B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00

B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ: IMMX) with a Buy rating and announces Price Target of $27.